Welcome to our dedicated page for Aspira Womens Health news (Ticker: AWHL), a resource for investors and traders seeking the latest updates and insights on Aspira Womens Health stock.
Aspira Women's Health Inc. develops and commercializes noninvasive, AI-enhanced bio-analytics tests for gynecologic disease diagnostics and disease management. Its commercial portfolio includes OvaSuite, which offers OvaWatch and Ova1Plus blood tests to aid ovarian cancer risk assessment for women with an adnexal mass; Ova1Plus uses the FDA-cleared Ova1 and Overa tests in a reflex process.
Company news commonly covers product revenue and test pricing trends, laboratory-service agreements, clinical workflow partnerships, molecular laboratory expansion, and development work for endometriosis diagnostics such as ENDOinform. Updates also include equity financing, warrant activity, board and executive appointments, and business-development efforts tied to broader use of Aspira's ovarian cancer and endometriosis testing programs.
Aspira Women's Health Inc. (OTCQB:AWHL), an AI-enhanced bio-analytics women's health company, has completed its transition to the OTCQB markets exchange, with trading beginning on May 7, 2025. CEO Mike Buhle emphasized this move as a positive step for shareholders, highlighting the company's strategic focus on cost reduction, controlled capital raises to minimize dilution, and leveraging non-dilutive capital sources for short-term business objectives.
Aspira Women's Health (OTC PINK:AWHL) has successfully submitted its third milestone under the $10 million ARPA-H award program, making it eligible for an additional $1.5 million payment expected in Q2 2025. The milestone focused on analytical development steps, including a biomarker technical report and voice of customer study framework for their ENDOinform™ program.
The company has already secured $3.5 million through three milestone submissions and anticipates receiving $2.0 million in fourth and fifth milestone payments by end-2025, with the remaining $3.0 million expected in 2026. The funding supports Aspira's development of an AI-enabled multi-marker blood test for endometriosis detection, leveraging technology from their successful ovarian cancer risk assessment tests.
Aspira Women's Health (NASDAQ:AWH), a bio-analytical based women's health company specializing in gynecologic disease diagnostic tools, has announced a trading symbol change. Starting April 17, 2025, the company's Common Stock will transition from trading under 'AWH' to trading under the new symbol 'AWHL' on the OTC Markets Group platforms.